Table 1.
Baseline Patient Characteristics for Any Patient Who Received Ceftazidime-Avib actam for Presumed Carbapenem-Resistant Gram-negative Infections
| Variable | Values |
|---|---|
| Age, median (IQR), years | 59.7 (49.1–70.4) |
| Sex | |
| Male | 914 (60) |
| Female | 610 (40) |
| Race | |
| White | 924 (60) |
| African American | 347 (23) |
| Other | 196 (13) |
| Unknown | 57 (4) |
| Comorbid conditiona | |
| Congestive heart failure | 426 (28) |
| Diabetes mellitus | 425 (28) |
| Transplant | 58 (4) |
| Malignancy | 79 (5) |
| Dialysis | 171 (11) |
| Tracheostomy | 202 (13) |
| Chronic kidney disease | 544 (36) |
| Neutropenia | 82 (5) |
| Presumed site of infectionb | |
| Abdominal | 286 (19) |
| Bacteremia | 95 (6) |
| Central nervous system | 9 (0.6) |
| Central venous catheter | 126 (8) |
| Respiratory | 590 (39) |
| Skin/soft tissue | 157(10) |
| Urinary | 510 (34) |
| Unknown/other | 380 (25) |
| APR-DRG severity of Illness | |
| Minor | 11 (0.7) |
| Moderate | 104 (7) |
| Major | 475 (32) |
| Extreme | 899 (60) |
| APR-DRG risk of mortality | |
| Minor | 79 (5) |
| Moderate | 256 (17) |
| Major | 584 (39) |
| Extreme | 570 (38) |
| ICU during first dose | 460 (49) |
| Vasopressor administrationc | 633 (42) |
| Mechanical ventilation | 241 (16) |
| Overall length of stay, median (IQR), days | 19 (3.5–34.5) |
Data are shown as n (%) unless otherwise indicated. N = 1524 patients.
Abbreviations: APR-DRG, All Patient Refined Diagnosis Related Group; ICU, intensive care unit; IQR, interquartile range.
aComorbid conditions reported on admission (see Supplementary Table 1 for list of associated International Classification of Diseases, 9th and 10th revision, codes).
bNon–mutually exclusive.
cDefined as administration of dopamine, epinephrine, norepinephrine, phenylephrine, or vasopressin ±1 day from initial ceftazidime-avibactam administration.